US4252796A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stable water-in-oil emulsions
Assignee: Individual
•
Filing: 1979-08-17
•
Granted: 1981-02-24
•
Expires: 1999-08-17
Abstract
Abstract Stabilized water-in-oil emulsions useful as vehicles for cosmetics and for therapeutic compositions to be topically applied is disclosed. The emulsions utilize a concentration of from 0.001 to 0.9% by weight of at least one of the aluminum containing compound as a primary emulsion stabilizer. A stable water-in-oil emulsion may also be formulated by utilizing from 0.001 to 0.2% of magnesium hydroxide or magnesium oxide as a primary emulsion stabilizer. This emulsion may be acidified to a desired pH with secondary emulsion stabilizer such as phosphoric acid, metallic chloride or metallic chlorohydroxide.
Inventors
- 👤 Ruey J. Yu
- 👤 Eugene J. Van Scott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:41
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/02; A61K8/04; A61K8/06; A61K8/064; A61K47/00; A61K47/02; A61K8/18; A61K8/19; A61K8/26; A61K9/00; A61K9/0012; A61K9/0014; A61K9/10; A61K9/107; A61Q; A61Q19/00
Claims Analysis
Total Claims: 40
Claim 1
Independent Claim
106 words
A method for stabilizing a water-in-oil emulsion for topical application to the human body so that said emulsion will be stable when stored for at least one month at an elevated temperature and stable when subjected to freezing with subsequent thawing to room temperature comprising: admixing an oil based dispersion medium, an emulsifying agent, and a water based, aqueous dispersed phase and a stabilizing effective amount of at least one member selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate.
Claim 2
Independent Claim
106 words
A method for stabilizing a water-in-oil emulsion for topical application to the human body so that said emulsion will be stable when stored for at least one month at an elevated temperature and stable when subjected to freezing with subsequent thawing to room temperature comprising: admixing an oil based dispersion medium, an emulsifying agent, and a water based, aqueous dispersed phase and a stabilizing effective amount of at least one member selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate.
Claim 3
Dependent Claim
20 words
The method of claim 1 wherein said member is present in an amount of up to about 0.9% by weight.
Claim 4
Dependent Claim
20 words
The method of claim 1 wherein said member is present in an amount of at least about 0.001% by weight.
Claim 5
Dependent Claim
39 words
The method of claim 1 wherein the oil based dispersion medium comprises at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate.
Claim 6
Dependent Claim
31 words
The method of claim 1 wherein the water based, aqueous dispersed phase comprises water and at least one member selected from the group consisting of propylene glycol, glycerol, 1,3-butanediol, and sorbitol.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein the emulsifying agent is a member selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate.
Claim 8
Independent Claim
149 words
A method for stabilizing a water-in-oil emulsion for topical application to the human body so that said emulsion will be stable when stored for at least one month at an elevated temperature and stable when subjected to freezing and subsequent thawing to toom temperature comprising: admixing an oil base dispersion medium, an emulsifying agent, and a water based, aqueous dispersed phase and a stabilizing effective amount of each of a primary stabilizer selected from the group consisting of magnesium hydroxide and magnesium oxide and a secondary stabilizer selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, aluminum acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride, and zirconium oxychloride.
Claim 9
Independent Claim
149 words
A method for stabilizing a water-in-oil emulsion for topical application to the human body so that said emulsion will be stable when stored for at least one month at an elevated temperature and stable when subjected to freezing and subsequent thawing to toom temperature comprising: admixing an oil base dispersion medium, an emulsifying agent, and a water based, aqueous dispersed phase and a stabilizing effective amount of each of a primary stabilizer selected from the group consisting of magnesium hydroxide and magnesium oxide and a secondary stabilizer selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, aluminum acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride, and zirconium oxychloride.
Claim 10
Dependent Claim
22 words
The method of claim 7 wherein said primary stabilizer is present in an amount of from about 0.001% to 2.0%, by weight.
Claim 11
Dependent Claim
22 words
The method of claim 7 wherein said secondary stabilizer is present in an amount of from about 0.001% to 0.9%, by weight.
Claim 12
Dependent Claim
33 words
The method of claim 7 wherein said secondary stabilizer is a 10% aqueous solution of phosphoric acid present in a concentration ratio of 0.1 to 0.9 ml per 100 gms of said emulsion.
Claim 13
Dependent Claim
21 words
The method of claim 7 wherein said secondary stabilizer is present in an amount of at least about 0.1%, by weight.
Claim 14
Dependent Claim
26 words
The method of claim 7 wherein said secondary stabilizer is aluminum chlorohydroxide present in a concentration of no more than 0.9% by weight of said emulsion.
Claim 15
Dependent Claim
39 words
The method of claim 7 wherein the oil based dispersion medium comprises at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate.
Claim 16
Dependent Claim
31 words
The method of claim 7 wherein the water based, aqueous dispersed phase comprises water and at least one member selected from the group consisting of propylene glycol, glycerol, 1,3-butanediol, and sorbitol.
Claim 17
Dependent Claim
23 words
The method of claim 7 wherein the emulsifying agent is a member selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate.
Claim 18
Independent Claim
149 words
A method for improving the efficacy of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotin-amide, 6-aminonicotinic acid methyl ester, and anthraline which is effective to alleviate the symptoms of inflammatory skin diseases psoriasis and eczema by topical application to involved areas of the human body comprising: providing a stabilized water-in-oil emulsion vehicle for said compound which is stable when stored for at least one month at an elevated temperature and stable when subjected to freezing with subsequent thawing to room temperature by admixing an oil based dispersion medium, an emulsifying agent and a water based dispersion phase with a stabilizing effective amount of at least one member selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium, tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate.
Claim 19
Independent Claim
149 words
A method for improving the efficacy of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotin-amide, 6-aminonicotinic acid methyl ester, and anthraline which is effective to alleviate the symptoms of inflammatory skin diseases psoriasis and eczema by topical application to involved areas of the human body comprising: providing a stabilized water-in-oil emulsion vehicle for said compound which is stable when stored for at least one month at an elevated temperature and stable when subjected to freezing with subsequent thawing to room temperature by admixing an oil based dispersion medium, an emulsifying agent and a water based dispersion phase with a stabilizing effective amount of at least one member selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium, tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate.
Claim 20
Dependent Claim
20 words
The method of claim 16 wherein said member is present in an amount of up to about 0.9% by weight.
Claim 21
Dependent Claim
20 words
The method of claim 16 wherein said member is present in an amount of at least about 0.001% by weight.
Claim 22
Dependent Claim
39 words
The method of claim 16 wherein the oil based dispersion medium comprises at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate.
Claim 23
Dependent Claim
31 words
The method of claim 16 wherein the water based, aqueous dispersed phase comprises water and at least one member selected from the group consisting of propylene glycol, glycerol, 1,3-butanediol, and sorbitol.
Claim 24
Dependent Claim
23 words
The method of claim 16 wherein the emulsifying agent is a member selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate.
Claim 25
Independent Claim
192 words
A method for improving the efficacy of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotinamide, 6-aminonicotinic acid methyl ester and anthraline which is effective to alleviate the symptoms of inflammatory skin diseases psoriasis and eczema by topical application to involved areas of the human body comprising: providing a stabilized water-in-oil emulsion vehicle for said compound which is stable when stored for at least one month at an elevated temperature, and stable when subjected to freezing with subsequent thawing to room temperature by admixing an oil based dispersion medium, an emulsifying agent and a water based dispersion phase with a stabilizing effective amount of each of a primary stabilizer selected from the group consisting of magnesium hydroxide and magnesium oxide and a secondary stabilizer selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, aluminum acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride and zirconium oxychloride.
Claim 26
Independent Claim
192 words
A method for improving the efficacy of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotinamide, 6-aminonicotinic acid methyl ester and anthraline which is effective to alleviate the symptoms of inflammatory skin diseases psoriasis and eczema by topical application to involved areas of the human body comprising: providing a stabilized water-in-oil emulsion vehicle for said compound which is stable when stored for at least one month at an elevated temperature, and stable when subjected to freezing with subsequent thawing to room temperature by admixing an oil based dispersion medium, an emulsifying agent and a water based dispersion phase with a stabilizing effective amount of each of a primary stabilizer selected from the group consisting of magnesium hydroxide and magnesium oxide and a secondary stabilizer selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, aluminum acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride and zirconium oxychloride.
Claim 27
Dependent Claim
22 words
The method of claim 22 wherein said primary stabilizer is present in an amount of from about 0.001% to 2.0%, by weight.
Claim 28
Dependent Claim
22 words
The method of claim 22 wherein said secondary stabilizer is present in an amount of from about 0.001% to 0.9%, by weight.
Claim 29
Dependent Claim
33 words
The method of claim 22 wherein said secondary stabilizer is a 10% aqueous solution of phosphoric acid present in a concentration ratio of 0.1 to 0.9 ml per 100 gms of said emulsion.
Claim 30
Dependent Claim
21 words
The method of claim 22 wherein said secondary stabilizer is present in an amount of at least about 0.1%, by weight.
Claim 31
Dependent Claim
26 words
The method of claim 22 wherein said secondary stabilizer is aluminum chlorohydroxide present in a concentration of no more than 0.9% by weight of said emulsion.
Claim 32
Dependent Claim
39 words
The method of claim 22 wherein the oil based dispersion medium comprises at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate.
Claim 33
Dependent Claim
31 words
The method of claim 22 wherein the water based, aqueous dispersed phase comprises water and at least one member selected from the group consisting of propylene glycol, glycerol, 1,3-butanediol, and sorbitol.
Claim 34
Dependent Claim
23 words
The method of claim 22 wherein the emulsifying agent is a member selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate.
Claim 35
Dependent Claim
153 words
A stable water-in-oil emulsion for use as a vehicle for topical application to the human body with cosmetic or medicinal compositions or compounds comprising: an oil phase dispersion medium including at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate; an emulsifying agent selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate; an aqueous phase dispersed therein including at least one member selected from the group consisting of water, propylene glycol, glycerol, 1,3-butanediol, and sorbitol; and a stabilizing agent dispersed throughout said emulsion selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate present in a concentration of from 0.001 to 0.9 percent by weight of the total composition.
Claim 36
Dependent Claim
153 words
A stable water-in-oil emulsion for use as a vehicle for topical application to the human body with cosmetic or medicinal compositions or compounds comprising: an oil phase dispersion medium including at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate; an emulsifying agent selected from the group consisting of sorbitan sesquioleate and sorbitan monooleate; an aqueous phase dispersed therein including at least one member selected from the group consisting of water, propylene glycol, glycerol, 1,3-butanediol, and sorbitol; and a stabilizing agent dispersed throughout said emulsion selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, aluminum phosphate, and aluminum acetoacetate present in a concentration of from 0.001 to 0.9 percent by weight of the total composition.
Claim 37
Dependent Claim
37 words
The emulsion of claim 31 further comprising an anti-inflammatory effective amount of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotinamide, 6-aminonicotinic acid methyl ester, and anthralin dispersed throughout said emulsion.
Claim 38
Dependent Claim
200 words
A stable water-in-oil emulsion for use as a vehicle for topical application to the human body with cosmetic or medicinal compositions or compounds comprising: an oil phase dispersion medium including at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate; an emulsifying agent selected from the group consisting of sorbitan sesquioleate, and sorbitan monooleate; an aqueous phase dispersed therein including at least one member selected from the group consisting of water, propylene glycol, glycerol, 1-3 butanediol, and sorbitol; and a primary stabilizing agent selected from the group consisting of magnesium hydroxide and magnesium oxide present in a concentration of 0.001 to 2.0%, by weight and a secondary stabilizing agent selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, ferric chloride, acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, aluminum phosphate, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride and zirconium oxychloride present in a concentration of from 0.001 to 0.9%, by weight.
Claim 39
Dependent Claim
200 words
A stable water-in-oil emulsion for use as a vehicle for topical application to the human body with cosmetic or medicinal compositions or compounds comprising: an oil phase dispersion medium including at least one member selected from the group consisting of petrolatum, mineral oil, beeswax, chicken fat, animal fat, vegetable oil, squalene, squalane, isopropyl myristate, and isopropyl palmitate; an emulsifying agent selected from the group consisting of sorbitan sesquioleate, and sorbitan monooleate; an aqueous phase dispersed therein including at least one member selected from the group consisting of water, propylene glycol, glycerol, 1-3 butanediol, and sorbitol; and a primary stabilizing agent selected from the group consisting of magnesium hydroxide and magnesium oxide present in a concentration of 0.001 to 2.0%, by weight and a secondary stabilizing agent selected from the group consisting of aluminum chloride, aluminum chlorohydroxide, aluminum dichlorohydroxide, aluminum zirconium chlorohydroxide, aluminum sesquichlorohydroxide, aluminum zirconium trichlorohydroxide, aluminum zirconium tetrachlorohydroxide, aluminum zirconium pentachlorohydroxide, sodium aluminum chlorohydroxy lactate, ferric chloride, acetoacetate, phosphoric acid, aluminum lactate, aluminum nitrate, aluminum hydroxide, aluminum phosphate, ferric chloride, ferric sulfate, zinc chloride, calcium chloride, sodium aluminum lactate, zirconium lactate, zirconium hydroxide, zirconium chloride and zirconium oxychloride present in a concentration of from 0.001 to 0.9%, by weight.
Claim 40
Dependent Claim
37 words
The emulsion of claim 33 further comprising an anti-inflammatory effective amount of a medicinal compound selected from the group consisting of hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-21-acetate, triamcinolone acetonide, 6-aminonicotinamide, 6-aminonicotinic acid methyl ester, and anthralin dispersed through said emulsion.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-02-24 | 1984-08-25 | 1985-02-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-02-24 | 1988-08-25 | 1989-02-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-02-24 | 1992-08-25 | 1993-02-24 | $7700.00 | Window Closed / Lapsed |